Yes, iPSCs hold promise for cancer immunotherapy. By differentiating iPSCs into immune cells such as T-cells or dendritic cells, researchers can develop new strategies to boost the immune system's ability to target and destroy cancer cells. This approach is being explored to create personalized immunotherapies.
